Similar articles

Abstract: Objective: To observe and compare the efficacy of intratympanic application of dexamethasone (DXM) for the treatment of refractory sudden sensorineural hearing loss (SSNHL), the DXM was given in three different ways: by tympanic membrane injection, by drip through a ventilation tube, and by perfusion through a round window catheter. Methods: We conducted a nonrandomized retrospective clinical trial involving 55 patients with refractory SSNHL. For 21 patients (the perfusion group), DXM (2.5 mg/0.5 ml) was perfused transtympanically through a round window catheter using an infusion pump for 1 h twice a day for 7 d giving a total amount of 35.0 mg. For 23 patients (the injection group), DXM (2.5 mg/time) was injected by tympanic membrane puncture at intervals of 2 d on a total of four occasions giving a total amount of 10.0 mg. For 11 patients (the drip group), DXM (2.5 mg/0.5 ml) was dripped via a ventilation tube placed by myringotomy, once on the first day and twice a day for the remaining 6 d giving a total amount of 32.5 mg. Thirty-two patients with refractory SSNHL who refused to undertake further treatments were defined as the control group. Hearing recovery and complications were compared among the groups. Hearing results were evaluated based on a four-frequency (0.5, 1.0, 2.0, 4.0 kHz) pure tone average (PTA). Results: Post-treatment audiograms were obtained one month after treatments were completed. The improvements in average PTA for the perfusion, injection, and drip groups were 9.0, 8.6, and 1.7 dB, respectively. Hearing improvement was significantly greater in the perfusion and injection groups than in the control group (1.4 dB) (P<0.05). In the perfusion group, 8 out of 21 patients (38.1%) had a PTA improvement of 15‒56 dB (mean 29.8 dB); in the injection group, 8 out of 23 patients (34.8%) had a PTA improvement of 16‒54 dB (mean 24.9 dB); in the drip group, 1 of 11 patients (9.1%) had a PTA improvement of 26.0 dB; in the control group, 3 out of 32 patients (9.4%) had a PTA improvement of 15‒36 dB (mean 14.9 dB). Conclusions: Topical intratympanic application of DXM is a safe and effective method for the treatment of SSNHL cases that are refractory to conventional therapies.

[1]Banerjee, A., Parnes, L.S., 2005. Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol. Neurotol., 26(5):878-881.

[2]Barrs, D.M., 2004. Intratympanic corticosteroids for Meniere’s disease and vertigo. Otolaryngol. Clin. North Am., 37(5):955-972.

[3]Chen, C.Y., Halpin, C., Rauch, S.D., 2003. Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis. Otol. Neurotol., 24(5):728-733.

[4]Choung, Y.H., Park, K., Shin, Y.R., Cho, M.J., 2006. Intratympanic dexamethasone injection for refractory sudden sensorineural hearing loss. Laryngoscope, 116(5):747-752.

[5]Dodson, K.M., Sismanis, A., 2004. Intratympanic perfusion for the treatment of tinnitus. Otolaryngol. Clin. North Am., 37(5):991-1000.

[6]Fetterman, B.L., Saunders, J.E., Luxford, W.M., 1996. Prognosis and treatment of sudden sensorineural hearing loss. Am. J. Otol., 17(4):529-536.

[7]Gianoli, G.J., Li, J.C., 2001. Transtympanic steroids for treatment of sudden hearing loss. Otolaryngol. Head Neck Surg., 125(3):142-146.

[8]Haynes, D.S., O′Malley, M., Cohen, S., Watford, K., Labadie, R.F., 2007. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope, 117(1):3-15.

[9]Herr, B.D., Marzo, S.J., 2005. Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol. Head Neck Surg., 132(4):527-531.

[10]Hughes, G.S., Freedman, M.A., Haberkamp, T.J., Guay, M.E., 1996. Sudden sensorineural hearing loss. Otolaryngol. Clin. North Am., 29(3):393-405.

[11]Jeyakumar, A., Frencis, D., Doerr, T., 2006. Treatment of idiopathic sudden sensorineural hearing loss. Acta Otolaryngol., 126(7):708-713.

[12]Kopke, R., Hoffer, M., Wester, D., 2001. Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol. Neurotol., 22(4):475-479.

[13]Lefebvre, P.P., Staecker, H., 2002. Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol., 122(7):698-702.

[14]Lu, Y.D., Ren, J.H., Wu, W.J., Yin, T.F., Tang, Y.Y., Xie, D.H., 2006. Intratympanic dexamethasone for sudden sensorineural hearing loss. J. Clin. Otorhinolaryngol., 20:11-12 (in Chinese).

[15]Parnes, L.S., Sun, A.H., Freeman, J., 1999. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope, 109(s91):1-17.

[16]Rauch, S.D., 2004. Intratympanic steroids for sensorineural hearing loss. Otolaryngol. Clin. North Am., 37(5):1061-1074.

[17]Ren, J.H., Lu, Y.D., Yin, T.F., Liu, B., Ge, Y.L., 2006. Intratympanic dexamethasone injection for intractable sudden sensorineural hearing loss. J. Clin. Otorhinolaryngol., 20:219-221 (in Chinese).

[18]Roebuck, J., Chang, C.Y., 2006. Efficacy of steroid injection on idiopathic sudden sensorineural hearing loss. Otolaryngol. Head Neck Surg., 135(2):276-279.

[19]Wilson, W.R., Byl, F.M., Laird, N., 1980. The efficacy of steroids in the treatment of idiopathic sudden hearing loss: a double-blind clinical study. Arch. Otolaryngol., 106(12):772-776.

[20]Zadeh, M.H., Storper, I.S., Spitzer, J.B., 2003. Diagnosis and treatment of sudden-onset sensorineural hearing loss: a study of 51 patients. Otolaryngol. Head Neck Surg., 128(1):92-98.